Drugs / Tregs
Tregs
Trials 5 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT02428309 | Aug 2015 → Sep 2016 | discoid lupus erythematosus, systemic lupus erythematosus | National Institute of Allergy and Infectious Diseases (NIAID) | Terminated | No outcome recorded |
| Phase 1 | NCT02088931 | Mar 2014 → Dec 2016 | disease related to solid organ transplantation | University of California, San Francisco | Completed | No outcome recorded |
| Phase 1 | NCT01210664 | Nov 2010 → Dec 2016 | type 1 diabetes mellitus | University of California, San Francisco | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT03460795 | Jun 2020 → Mar 2025 | cirrhosis of liver | Nanjing Medical University | Unknown | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06688331 | Mar 2025 → Dec 2032 expected | type 1 diabetes mellitus | PolTREG S.A. | Recruiting | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2020-10-22 | Daiichi Sankyo | Daiichi Sankyo Initiates Phase 1 Trial with Immuno-Oncology Therapy DS-1055 Targeting GARP on Activated Regulatory T Cells daiichisankyo.com ↗ |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Tregs | “The investigational therapy under study in this trial, regulatory T cells (Tregs), offers the hope of stabilizing further destruction of insulin producing beta cells in type 1 diabetes.” NCT01210664 ↗3“This study uses Regulatory T cells (Tregs), which are found in the blood and are part of the immune system that stops other immune cells from working.” NCT02088931 ↗ |
| Known as | Ex vivo Expanded Human Autologous Polyclonal Regulatory T Cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02428309 ↗ |
| Known as | Regulatory T cells | “The investigational therapy under study in this trial, regulatory T cells (Tregs), offers the hope of stabilizing further destruction of insulin producing beta cells in type 1 diabetes.” NCT01210664 ↗2“Besides, regulatory T cells(Tregs) had been proved as an immune regualtory T cell subsets, which could reduce immune cell activation and reduce liver injury severity.” NCT03460795 ↗ “This study uses Regulatory T cells (Tregs), which are found in the blood and are part of the immune system that stops other immune cells from working.” NCT02088931 ↗ |
| Modality | Cell therapy | “Treg adoptive cell therapy” PMID 34324441 ↗ Sep 2021 |
| Route | Intravenous | “intravenous infusion of ex vivo selected and expanded autologous polyclonal Tregs” NCT01210664 ↗ |